ISPE Awards Pfizer Ireland Pharmaceuticals as the 2014 Facility of the Year Awards Overall Winner
International Society for Pharmaceutical Engineers (ISPE) has announced Pfizer Ireland Pharmaceuticals as the 2014 Facility of the Year Awards (FOYA) Overall Winner at the society's annual meeting in Las Vegas, NV.
Pfizer Ireland's Network Strategy Implementation (NSI) Expansion Capacity project challenged the company to add capacity by re-purposing an existing manufacturing space for a new vaccine suite and a new multiproduct small-to-medium scale drug substance bioprocess suite at the Grange Castle plant in Clondalkin, South County Dublin.
"The NSI Expansion Capacity project exemplified the mission of FOYA," said ISPE President and CEO John Bournas. "Pfizer Ireland's vision of empowerment and operational excellence enabled the company to produce a world-class manufacturing environment and expand the capacity of its biotech operations on an aggressive timeline."
Throughout the project, Pfizer Ireland utilised a Lean Management Strategy and a 5S programme in the design process to ensure flow and operations. In addition, a Six Sigma toolkit was developed for all project personnel, and all production processes were value stream-mapped. The project team also ensured the new manufacturing suites included the latest technologies (i.e. EBR, PAT and Disposable Bag).
"We are excited to recognize Pfizer Ireland as an innovator in operational excellence," said Chair of the FOYA Judging Panel James Breen, "The society was impressed with the NSI Capacity Expansion project and the company's ability to effectively manage the challenges of maintaining supply with the demolition of existing facilities, new construction, and start-up and integration activities."
Celebrating its tenth year, FOYA continues to showcase the pharmaceutical manufacturing industry's accomplishments in facility design, construction and operation, while sharing the development of new applications of technology and cutting-edge approaches.
"Pfizer Ireland and previous FOYA winners represent the shared commitment and dedication of individuals and companies worldwide striving to enhance patient health and safety through innovation and advancements in pharmaceutical manufacturing technology," said Bournas. "The society and its leadership is proud of the accomplishments of all award winners.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance